SLC5A1 and Hypoglycemia: Importantly, because of this high selectivity for SGLT2, glucose is reabsorbed by SGLT1 at a low plasma glucose level, and thus tofogliflozin has low risk of hypoglycemia, unlike other currently available type 2 diabetes medications.